Evidence map›Paper›PMID 42903824›Full record

ArticleiScience2026

A dual recombinant strategy to quantify PreS1 antibody in hepatitis B patients with genotype B or C virus by ELISA.

Yumin Li, Xiaoyu Wen, Jing Zhan, Tingting Cao, Xiumei Chi, Huanyi Cheng, Qingrui Huang, Wenyi Zhang, Junqi Niu, Huan Du and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yumin LiKey Laboratory of Bionic Engineering (Ministry of Education), Jilin University, Changchun 130022, China.
Xiaoyu WenDepartment of Hepatology, The First Hospital of Jilin University, Jilin University, Changchun 130021, China.
Jing ZhanDepartment of Gastroenterology and Endoscopy Center, The First Hospital of Jilin University, Jilin University, Changchun 130021, China.
Tingting CaoDepartment of Gastroenterology and Endoscopy Center, The First Hospital of Jilin University, Jilin University, Changchun 130021, China.
Xiumei ChiCore Facility of the First Hospital of Jilin University, Jilin University, Changchun 130021, China.
Huanyi ChengBeijing Abace Biotechnology, Beijing 100176, China.
Qingrui HuangBeijing Abace Biotechnology, Beijing 100176, China.
Wenyi ZhangBeijing Abace Biotechnology, Beijing 100176, China.
Junqi NiuDepartment of Hepatology, The First Hospital of Jilin University, Jilin University, Changchun 130021, China.
Huan DuSchool of Chemistry and Environment, Southwest Minzu University, Chengdu 610041, China.
Zhenning LiuKey Laboratory of Bionic Engineering (Ministry of Education), Jilin University, Changchun 130022, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated levels of anti-preS1 antibodies in patients correlate with faster hepatitis B virus (HBV) clearance, since preS1 is vital for viral entry. However, accurate quantification of preS1 antibodies is hindered by the variation of HBV genotypes. Herein, a quantitative preS1 antibody assay was developed for Chinese patients with predominant HBV genotypes B and C. First, to address genotype diversity, we constructed a dual recombinant protein combining genotype B and C preS1. Second, a mouse-human chimeric antibody with high and comparable affinity for both B and C preS1 is developed as the standard for quantification by screening and cloning. An optimized ELISA kit using these components demonstrated good specificity, accuracy, reproducibility and stability, with a linear range of 10-100 ng/mL. This approach extends the patient coverage in China to over 95%, providing a valuable diagnostic tool. This work demonstrates a proof-of-concept model for developing broad-coverage assays for other multi-genotype viral diseases.

Indexed as

ELISAenzyme-linked immunosorbent assaygenotype-specific antibodyHBVhepatitis B viruspreS1quantitative diagnosis

Identifiers

PMID42903824
PMCPMC13682388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.